Latest news with #Komen
Business Wire
22-05-2025
- Health
- Business Wire
Millions at Risk: Komen Speaks Out Against House Reconciliation Bill
DALLAS--(BUSINESS WIRE)-- Susan G. Komen ®, the world's leading nonprofit breast cancer organization, is deeply troubled by passage of legislation by the House of Representatives which drastically cuts funding for federal health insurance programs and implements damaging reforms. The Congressional Budget Office estimates these changes, combined with the failure to renew health care tax credits, could cause nearly 14 million people to lose their insurance coverage, increasing the U.S. uninsured rate by 30%. Put simply, if enacted into law, this legislation will inflict serious harm on the breast cancer community. This health coverage is essential to ensuring timely access to breast cancer screening, diagnosis and treatment — care that might otherwise be delayed until the disease is more advanced and expensive to treat. Share Medicaid and the Affordable Care Act (ACA) Marketplaces often serve as a lifeline for many people in the breast cancer community, from those seeking screening to those in treatment and beyond. In the U.S., more than 72 million people rely on Medicaid. In fact, 1 in 10 adults with a history of cancer utilize Medicaid for insurance coverage. Millions of others rely on plans offered through the ACA Marketplaces. This health coverage is essential to ensuring timely access to breast cancer screening, diagnosis and treatment — care that might otherwise be delayed until the disease is more advanced and expensive to treat. The National Breast and Cervical Cancer Early Detection Program, a state-federal partnership which aims to increase early detection among women with low-incomes, works in conjunction with state Medicaid programs to provide treatment for those who are diagnosed with breast cancer — an effort that maximizes our nation's investment in both programs. The bill requires work reporting requirements that would restrict access to quality and affordable healthcare for millions of patients. Even if breast cancer patients qualify for exceptions from the work reporting requirements, which remains unclear, they would still be required to navigate through administrative red tape to demonstrate their qualification. Additionally, this legislation proposes eligibility checks on Medicaid enrollees every 6 months, further increasing the administrative burden for enrollees, which is the last thing a person undergoing cancer treatment should have to face. Additional policies included in the bill make several changes to ACA Marketplace plans, including codifying harmful regulations, shortening the open enrollment period, and enhancing eligibility checks, eroding coverage for the millions of Americans, including breast cancer patients and survivors. Komen urges Congress to do better for the breast cancer community and asks the Senate to reject the policies which will hurt the breast cancer patients, survivors and many other Americans when they consider the budget reconciliation bill next. Join us in this effort by contacting your U.S. Senators here. Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit or call 1-877 GO KOMEN. Connect with us on social at
Yahoo
22-05-2025
- Health
- Yahoo
Millions at Risk: Komen Speaks Out Against House Reconciliation Bill
Breast cancer patients could lose coverage, face delays in critical care DALLAS, May 22, 2025--(BUSINESS WIRE)--Susan G. Komen®, the world's leading nonprofit breast cancer organization, is deeply troubled by passage of legislation by the House of Representatives which drastically cuts funding for federal health insurance programs and implements damaging reforms. The Congressional Budget Office estimates these changes, combined with the failure to renew health care tax credits, could cause nearly 14 million people to lose their insurance coverage, increasing the U.S. uninsured rate by 30%. Put simply, if enacted into law, this legislation will inflict serious harm on the breast cancer community. Medicaid and the Affordable Care Act (ACA) Marketplaces often serve as a lifeline for many people in the breast cancer community, from those seeking screening to those in treatment and beyond. In the U.S., more than 72 million people rely on Medicaid. In fact, 1 in 10 adults with a history of cancer utilize Medicaid for insurance coverage. Millions of others rely on plans offered through the ACA Marketplaces. This health coverage is essential to ensuring timely access to breast cancer screening, diagnosis and treatment — care that might otherwise be delayed until the disease is more advanced and expensive to treat. The National Breast and Cervical Cancer Early Detection Program, a state-federal partnership which aims to increase early detection among women with low-incomes, works in conjunction with state Medicaid programs to provide treatment for those who are diagnosed with breast cancer — an effort that maximizes our nation's investment in both programs. The bill requires work reporting requirements that would restrict access to quality and affordable healthcare for millions of patients. Even if breast cancer patients qualify for exceptions from the work reporting requirements, which remains unclear, they would still be required to navigate through administrative red tape to demonstrate their qualification. Additionally, this legislation proposes eligibility checks on Medicaid enrollees every 6 months, further increasing the administrative burden for enrollees, which is the last thing a person undergoing cancer treatment should have to face. Additional policies included in the bill make several changes to ACA Marketplace plans, including codifying harmful regulations, shortening the open enrollment period, and enhancing eligibility checks, eroding coverage for the millions of Americans, including breast cancer patients and survivors. Komen urges Congress to do better for the breast cancer community and asks the Senate to reject the policies which will hurt the breast cancer patients, survivors and many other Americans when they consider the budget reconciliation bill next. Join us in this effort by contacting your U.S. Senators here. About Susan G. Komen® Susan G. Komen® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit or call 1-877 GO KOMEN. Connect with us on social at View source version on Contacts press@
Business Wire
13-05-2025
- Health
- Business Wire
Purpose in Action: Susan G. Komen's 2025 Impact Report on Progress and Urgent Needs in the Fight Against Breast Cancer
DALLAS--(BUSINESS WIRE)--Susan G. Komen®, the world's leading breast cancer organization, today released its 2025 Annual Impact Report, highlighting a year of progress made possible by the dedication of its donors, volunteers and partners. Breast cancer is the second leading cause of cancer death among women in the U.S. and is the most common cancer among women worldwide. What's more, it's estimated that more than 168,000 people in the U.S. are living with metastatic breast cancer (MBC), also known as stage 4, the most advanced and incurable stage of breast cancer. This year alone, nearly 43,000 people in the U.S. are expected to die from breast cancer — with MBC responsible for most of these deaths. Komen's impact report highlights the critical progress made in the fight against breast cancer made possible by the passionate dedication of its donors, volunteers and partners — and the hope for a brighter future driven by its nationwide community. Komen believes that to save lives, the community must focus on conquering aggressive and metastatic breast cancers and eliminating barriers to care to achieve health equity. To achieve the organization's goals, to date, Komen has invested nearly $2.5 billion in advocacy, community programs, education and patient support services, ensuring people are educated about the complexities of risk, screening, diagnosis and treatment for breast cancer and have access to the care they need. Komen has also invested nearly $1.1 billion in research making it the largest nonprofit contributor to the cause, second only to the U.S. government. This investment has led to new ways to prevent, detect, diagnose and treat breast cancer. 'Susan G. Komen's impact is woven into nearly every major breakthrough and patient-centered policy in the history of breast cancer, but we could never have come this far without the support of our community,' said Paula Schneider, Komen president and CEO. 'Our donors, volunteers, partners and fundraisers are the heart of our history and frankly, our future. Many come to Komen because they've been personally touched by this disease — and, as a breast cancer survivor, myself included. There is power in pain and hope alike, and the progress we've made is a testament to those who've turned their experience and grief into action.' Key Highlights from Komen's 2025 impact report include: Public Policy and Advocacy In 2024, Komen's Center for Public Policy introduced 41 bills in 34 states, with 16 signed into law, and played a key role in securing $329 million in federal and state funding for safety net screening programs through Komen's Center for Public Policy. Komen helped secure $47 billion in federal research funding, with 21 states introducing legislation focused on eliminating cost sharing for diagnostic and supplemental imaging and 8 states introducing legislation on eliminating step therapy requirements for MBC patients. More than 900 meetings were held with policymakers and staff. Research Over the past 30 years, Komen research funding has contributed to 20 new breast cancer-fighting drugs. Last year, Komen's investment added 26 new products to the research pipeline and engaged 1,093 participants in Komen-led research efforts like ShareForCures ®. Patient Care Last year, 42,895 direct patient services were provided to 35,904 people in need, along with $7.5 million in financial assistance granted to 17,087 people. Since 2021 when our Patient Care Center was established, nearly 144,000 people have received services, including over $31.9 million in financial assistance provided. Education Over 2.9 million people were reached through Komen's educational programs in the last year, including through our extensive About Breast Cancer web resource and over 180 education events such as the virtual Breast Cancer Breakthroughs sessions After attending one of Komen's educational programs, 90% of survey respondents indicated they had an improved understanding of breast cancer and 61% of survey respondents indicated they will take action to improve their breast health. Health Equity The second virtual Komen Health Equity Revolution Summit galvanized 400+ attendees for impactful discussions and solutions with public health and patient advocacy leaders from American Society of Clinical Oncology, ZERO Prostate Cancer, LGBT Cancer Network and more. Komen Ambassadors including Emmy-winning journalist and breast cancer survivor Gaby Natale, the first Latina to win three consecutive Emmys and Miss Black USA Kennedy Lucas, a young advocate, were activated to amplify diverse breast cancer voices and inspire action through digital storytelling. Metastatic Breast Cancer Komen expanded its impact on the MBC community through its MBC Impact Series and Komen's new Inside MBC video, amplifying the lived emotional experience of an MBC diagnosis and reaching thousands of people with lifesaving and life-affirming information. With proposed federal budget cuts for Fiscal Year 2026 threatening to erode decades of progress in the fight against breast cancer, continued funding especially for early detection programs, safety net care services and research has never been more critical. If these cuts proceed, Susan G. Komen will continue to stand as the leading breast cancer organization in the nation — but without sustained government support, lifesaving breakthroughs may be delayed, early detection efforts will be reduced, and patients will be left behind with poor outcomes to follow. As Komen continues to lead the charge against breast cancer, the 2025 Impact Report serves as both a reflection of what's been achieved and a call to action for what still needs to be accomplished. Every advancement — whether in research, patient care, education or policy — is fueled by the commitment of those who stand with Komen. 'With continued support, we can build on these incredible milestones to ensure everyone affected by this disease has access to the high-quality care, resources and support they need to survive and thrive after breast cancer,' added Schneider. 'The fight is far from over — but together, we will finish it.' Read the full report online. About Susan G. Komen ® Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit or call 1-877 GO KOMEN. Connect with us on social at
Business Wire
05-05-2025
- Health
- Business Wire
Susan G. Komen ® Announces New Date, Location for 2025 Miami/Ft. Lauderdale MORE THAN PINK Walk
MIAMI--(BUSINESS WIRE)-- Susan G. Komen ®, the world's leading breast cancer organization, today announced a new date and location for the 2025 Miami/Ft. Lauderdale MORE THAN PINK Walk that will take place this fall on Saturday, October 4 at the Miami-Dade County Fair and Exposition, uniting survivors, families and advocates in a powerful movement to fund research, provide patient support and drive meaningful change for those impacted by breast cancer. Every 12 minutes, a woman in the U.S. dies from breast cancer—and rates are rising among younger women. In Florida alone, more than 23,000 women will be diagnosed in 2025, and over 3,000 will lose their lives to the disease. While the death rate has dropped 44% since 1989, too many still lack access to the care that could save them. Experts estimate up to one-third of breast cancer deaths are preventable with timely, high-quality treatment. Funds raised at the Race/Walk fuel Komen's mission—supporting patients with free navigation, financial aid, emotional care, and lifesaving research 'We are excited to bring the community together at a new date and location this year,' said Sean Gross, Executive Director, Florida Susan G. Komen. 'This event isn't just about raising funds—it's about saving lives, ensuring equity in care, and standing with every person impacted by this disease. We invite everyone to walk with us, fight with us, and help create a future without breast cancer.' Additionally, Komen is thrilled to announce that Jessica Williams, a respected community leader, will serve as the Chair of this year's Walk. "I am truly honored to serve as the 2025 Miami/Fort Lauderdale MORE THAN PINK WALK, Executive Leadership Committee Chair,' said Williams. 'This cause is deeply personal to me, and I am proud to stand alongside a community so committed to creating hope, empowering survivors, and funding the fight for a cure for breast cancer. Together, we will make an extraordinary impact, one step, one story, and one life at a time." This year's MORE THAN PINK Walk will include an opening ceremony where survivors and those affected by breast cancer will share their personal stories. The day will also recognize those who have lost their life to the disease. Attendees will participate in a 5k Walk at their own pace through Tamiami Park, and vendor booths will be set up throughout the event site, offering giveaways and providing educational information. To register or learn more, visit: About Susan G. Komen ® Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit or call 1-877 GO KOMEN. Connect with us on social at
Forbes
23-04-2025
- Business
- Forbes
The Health Care Stock Fund With An Ulterior Motive
'I have never known much good done by those who affected to trade for the public good,' Adam Smith said. Maybe he'd have made an exception for the Simplify Health Care exchange-traded fund. All of its 0.5% fee revenue, after overhead, is donated to the Susan G. Komen Breast Cancer Foundation. The fund's portfolio manager, Michael F. Taylor, takes no salary. Private businesses that give away all profits and also succeed as businesses are scarce; the Newman's Own food branding operation, which has donated $600 million to children's causes, is unusual. An eleemosynary aim would seem to be even more out of place on Wall Street, where 'greed is good' is the mantra. 'This is the first true impact-investment ETF,' brags Taylor, 52, who retired young and prosperous from a hedge fund career. 'I have the luxury of not having to receive money for my efforts.' So far the fund has sent $250,000 to Komen. He picked Komen, he says, because it can effectively invest money in medical research—some $10 million a year, recently. Customers of the Simplify fund aren't making any sacrifices. The actively managed ETF, which opened in late 2021 and has attracted $144 million in assets, has averaged a 5.3% annual return since inception, per YCharts, matching the return of the giant Health Care Select SPDR fund, which passively tracks an index. Taylor is assuredly not running any closet index fund. His annual turnover is 210%, par for a hedgie but freakish for an ETF. The SPDR fund owns Merck, Biogen, Amgen and Pfizer. Taylor shuns all four because, he says, looming patent expirations will decimate their profits. Pfizer commits the additional sin of making Covid vaccines, which the iconoclastic Taylor views as no good. No one can accuse this guy of being shy about his opinions. At the beginning of the pandemic five years ago he was saying, loudly and impolitically, that the virus was a man-made Chinese concoction. Now he splutters about Moderna. Its mRNA vaccine can cause havoc with the immune system, he says, and might have to be withdrawn from the market. He may be wrong about that, but he has been right to avoid the stock, which is in the SPDR index fund. It's down from a high of $484 to a recent $35. Taylor is entitled to an opinion about viruses. After getting a master of science degree from Johns Hopkins he went to work for GenVec, a company trying to use viruses to deliver genes into the body. He was dismayed to discover that an awful lot of the job involved moving beakers from one table to another. 'I love the science. I just don't like doing it,' he says. 'I might as well have been a carpenter.' Something else bothered him. This was during one of Wall Street's manias for biotechnology, and GenVec's stock was being touted on television. He had a dim view of the company's prospects and wished he could bet against it. Solution: business school. After getting an MBA from the University of Rochester he went to work for a succession of money managers: Oppenheimer, Caxton, Citadel, Millennium. He relates that one of his successes was getting into Gilead, now a big company, when it was in the early stages of making drugs for HIV. Another was shorting Valeant, the high-flyer with factitious revenue growth. The Simplify ETF owns shares in some big companies familiar to health care investors, like Eli Lilly. Lilly looks expensive at 70 times trailing earnings but is going to enjoy a burst of revenue, Taylor predicts, given the recent decision by Medicare to cover its expensive weight-loss drug for patients who have sleep apnea. Overweight, sleep-deprived elderly patients also need an air pump, made by Resmed. Taylor holds that stock as well. Outside the mainstream medical companies, the Taylor portfolio can best be described as quirky. He owns Chewy. Most of its customers think of it as a dog food company. Taylor sees the payoff elsewhere, in the distribution of high-markup veterinary medicines. PureCycle Technologies is a money-losing firm working on a way to recycle polypropylene. What's it doing in the health care fund? Taylor was looking for beaten-up stocks that might rebound and put 'garbage stocks' into a search bar. Google served up a collection of waste management companies, including this one. Intrigued, he dug into the chemistry and concluded that PureCycle is on the cusp of commercialization that will yield billions in revenue. Simplify's rules allow up to 20% of assets to fall outside health care, and, when shares were trading below $4, off from a $32 high, the fund started buying. PureCycle recently closed above $7. Arcutis Biotherapeutics is another long-shot bet with a potentially big payoff. This money loser is developing biotech treatments for autoimmune disease. The SPDR health fund owns none of it; Taylor's fund has 8% of assets in the company. Immunology is as big a deal as virology. Future treatments for cancer and diseases such as psoriasis and multiple sclerosis will involve manipulations of the immune system. Taylor has a personal stake in immunology research. He suffers from an autoimmune disease that left him with crippling spinal pain until a recent experimental treatment involving lasers. The treatment worked. He's walking around now, after years of spending most days lying on his back. Investors blow hot and cold on developmental-stage companies like GenVec, PureCycle and Arcutis. In the past few years, they have been rather cool. Since Simplify Health Care opened, health care in general and biotech stocks in particular have underperformed the market. This optimistic risk taker is convinced that the market will turn in his favor. 'We're in a golden age of discovery and development in biotechnology, and only at the very beginning,' he says. 'Humans are going to be living longer and better lives.' Let's hope he's right. Editor's note: Market-related data points are as of March 12.
